You are here: Industry Insights > Heron

News List

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients E firstwordpharma
July 29, 2021
Heron Therapeutics, Inc. today announced the results from the HOPE Hernia-1 study of ZYNRELEF (bupivacaine and meloxicam) in hernia repair surgery have been published online by Pain and Therapy in an article entitled
Heron Announces Successful FDA Meeting for Postoperative Pain Treatment americanpharmaceuticalreview
September 23, 2020
Heron Therapeutics announced a successful Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment was reached on the plans for the Company to resubmit the New Drug Application (NDA) for HTX-011 for the management of p...
Heron Begins Phase 2 Clinical Study of Cinvanti for COVID-19 americanpharmaceuticalreview
July 27, 2020
Heron Therapeutics announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19).
Heron Receives CRL for HTX-011 for Postoperative Pain americanpharmaceuticalreview
July 08, 2020
Heron Therapeutics has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for HTX-011 for the management of postoperative pain.
Heron Announces Initiation of Study of HTX-034 for Postoperative Pain americanpharmaceuticalreview
May 28, 2020
Heron Therapeutics has initiated a Phase 1b/2 clinical study in patients undergoing bunionectomy of HTX-034, Heron's next-generation product for the treatment of postoperative pain.
Heron Announces FDA Approval of sNDA to Expand CINVANTI® Label for IV Push americanpharmaceuticalreview
February 28, 2019
Heron Therapeutics announced the U.S. Food and Drug Administration (FDA) has approved Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion...